A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

NCT07335562 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Sclerosis

Interventions

DRUG: BMS-986353
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Tocilizumab
DRUG: Rituximab
DRUG: Nintedanib

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Collaborators

[object Object]